Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.
about
Thrombolysis for acute ischaemic strokeThrombolysis (different doses, routes of administration and agents) for acute ischaemic strokeThree simple rules to ensure reasonably credible subgroup analysesThe benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialRecombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysisMechanical thrombectomy for emergent large vessel occlusion: a critical appraisal of recent randomized controlled clinical trialsThe transient intraluminal filament middle cerebral artery occlusion model as a model of endovascular thrombectomy in strokeBasilar Occlusion Syndromes: An UpdateIntravenous Thrombolysis for Acute Ischemic Stroke Within 3 Hours Versus Between 3 and 4.5 Hours of Symptom OnsetImaging of prehospital stroke therapeuticsImmune interventions in strokeThe Yin and Yang of innate immunity in strokeEffect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trialsReperfusion therapy of acute ischaemic stroke and acute myocardial infarction: similarities and differencesThe potential roles of 18F-FDG-PET in management of acute stroke patientsWake-up stroke: clinical characteristics, imaging findings, and treatment option - an updateNext-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'Cytoprotective-selective activated protein C therapy for ischaemic strokeMore outcomes than trials: a call for consistent data collection across stroke rehabilitation trialsThe exact science of stroke thrombolysis and the quiet art of patient selectionFingolimod for the treatment of neurological diseases-state of play and future perspectivesWarfarin anticoagulation exacerbates the risk of hemorrhagic transformation after rt-PA treatment in experimental stroke: therapeutic potential of PCCDeficiency in serine protease inhibitor neuroserpin exacerbates ischemic brain injury by increased postischemic inflammationIntravenous versus intra-arterial thrombolysis in ischemic stroke: a systematic review and meta-analysis.Acute Ischemic Stroke Treatment, Part 2: Treatment "Roles of Capillary Index Score, Revascularization and Time"Diagnosis and management of acute ischemic stroke: speed is criticalEndovascular therapy for ischemic strokeA concerted appeal for international cooperation in preclinical stroke researchThrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials ArchiveTime to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trialThe effect of out of hours presentation with acute stroke on processes of care and outcomes: analysis of data from the Stroke Improvement National Audit Programme (SINAP)Differences Between US and UK Adults in Stroke Preparedness: Evidence From Parallel Population-Based Community Surveys.Reperfusion therapies for acute ischemic stroke: an updateImaging recommendations for acute stroke and transient ischemic attack patients: A joint statement by the American Society of Neuroradiology, the American College of Radiology, and the Society of NeuroInterventional Surgery.Imaging recommendations for acute stroke and transient ischemic attack patients: a joint statement by the American Society of Neuroradiology, the American College of Radiology and the Society of NeuroInterventional SurgeryMultiparametric MRI and CT models of infarct core and favorable penumbral imaging patterns in acute ischemic stroke.CLOTBUST-hands free: initial safety testing of a novel operator-independent ultrasound device in stroke-free volunteers.Tissue at risk in acute stroke patients treated beyond 8 h after symptom onset.Evolution of intracerebral hemorrhage after intravenous tPA: reversal of harmful effects with mast cell stabilizationSelection of possible responders to thrombolytic therapy in acute ischemic stroke.
P2860
Q24194788-92E5299B-E1EA-43D8-80E6-BE7714B292B5Q24202641-8D9335AD-4D27-401C-B84B-4A16FADDD0C8Q24289039-A67998C6-8EFF-4906-9C19-76C860B72053Q24595579-9C490E46-3283-4B16-9854-B6E92DA8F7CEQ24595703-301671F0-F4B7-401D-A74C-2350F22D77F3Q26750614-BD108BDF-3C02-4399-86DD-8D641572561CQ26776379-20415998-FAE0-4293-8E10-086CF834301EQ26796468-5FC2BF47-B271-44E0-922C-E154CCA51F66Q26796477-56A91EBF-EBC1-470F-AE1D-6E62BAC487B3Q26797275-4CDC6D9C-39AD-484A-9FDA-D253E720AF65Q26797993-5F3CCB1A-271C-4BE2-9F8E-9EA6EEA08388Q26822268-18ECB777-9556-40FB-9BB0-E0FF2441884AQ26823902-67FE1F4D-E9E9-4881-A7C8-2CD45E9E79C4Q26824552-41F2F727-E49D-4B79-A6F6-7B7C68575E42Q26827823-EB2CAC70-CEA4-4FEE-B293-011E2BA60A49Q26862670-DDA72C4A-1E7B-408D-B97F-7EA80F79AED9Q26865345-FD2AC208-A0AD-4AEF-8764-5B2669062C49Q27009122-E8BDB462-F0FC-41A2-AFA1-BF0DDB0AFB4FQ27009182-03B1EA2F-C9D6-4EF7-B9D8-91C67354D5C1Q27011873-B98D30C8-80F3-49D4-9856-323891ED5EB3Q27026175-3DECBDF7-8D9C-43A5-B126-D9BA7B836435Q27316789-2FBB4269-A229-4854-A96A-0D8A1AADB19CQ27321143-4CB2052A-D015-488C-B3BA-19B1D6F624EDQ27692041-A6EDB554-0205-4B8C-AE7A-E889219C3298Q28083582-06380CC6-E358-424C-8D84-65ED245B6CF1Q28085439-817D77DA-8C4B-48B7-BDD8-5A4E56F694ABQ28088710-FA5C5137-D679-4551-B947-2A6C66F5BF2FQ28658665-A9FA3F43-ACD8-4697-A1A3-37AF42C11C3BQ28748178-1E8DCCF9-4903-4330-BD83-FC1F54A96166Q30000128-271D4651-76CE-4A12-81D4-7C3E9308D596Q30000684-D0854D26-EF60-4D25-8DDA-B9690F6E5809Q30202552-70DF2301-16DD-47B5-A11D-97FBFA5B27BFQ30399762-C345C530-424A-47FC-8A55-F7C6D98BAB2CQ30409698-B1817E80-2813-4D1B-8E0B-FD40A648BE6FQ30411178-ED14C502-6267-4F0B-A134-B1CAD6C5148AQ30415593-D0BBD92C-18B9-409B-8977-8C940CE29462Q30431298-2EDAD8C5-9AE1-45CA-8A0E-1D9457734A42Q30456573-FCA5404A-431A-4A57-87A8-9E14EB45C3A2Q30563965-7F21B05C-E286-4D3E-81B9-2D2EAD2F1D64Q30568984-F6FC1C11-6A7D-4770-8955-3837D2B26EAE
P2860
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Time to treatment with intrave ...... IS, NINDS, and EPITHET trials.
@en
Time to treatment with intrave ...... IS, NINDS, and EPITHET trials.
@nl
type
label
Time to treatment with intrave ...... IS, NINDS, and EPITHET trials.
@en
Time to treatment with intrave ...... IS, NINDS, and EPITHET trials.
@nl
prefLabel
Time to treatment with intrave ...... IS, NINDS, and EPITHET trials.
@en
Time to treatment with intrave ...... IS, NINDS, and EPITHET trials.
@nl
P2093
P50
P1433
P1476
Time to treatment with intrave ...... IS, NINDS, and EPITHET trials.
@en
P2093
Barbara C Tilley
D A De Silva
Danilo Toni
Dieter Meier
ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group
Erich Bluhmki
Gregory W Albers
Gregory del Zoppo
James C Grotta
P304
P356
10.1016/S0140-6736(10)60491-6
P407
P577
2010-05-01T00:00:00Z